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Abstract 
Background: It remains uncertain if prior use of oral anticoagulants (OACs) in COVID‑19 outpatients with multimor‑
bidity impacts prognosis, especially if cardiometabolic diseases are present. Clinical outcomes 30‑days after COVID‑19 
diagnosis were compared between outpatients with cardiometabolic disease receiving vitamin K antagonist (VKA) or 
direct‑acting OAC (DOAC) therapy at time of COVID‑19 diagnosis.
Methods: A study was conducted using TriNetX, a global federated health research network. Adult outpatients with 
cardiometabolic disease (i.e. diabetes mellitus and any disease of the circulatory system) treated with VKAs or DOACs 
at time of COVID‑19 diagnosis between 20‑Jan‑2020 and 15‑Feb‑2021 were included. Propensity score matching 
(PSM) was used to balance cohorts receiving VKAs and DOACs. The primary outcomes were all‑cause mortality, inten‑
sive care unit (ICU) admission/mechanical ventilation (MV) necessity, intracranial haemorrhage (ICH)/gastrointestinal 
bleeding, and the composite of any arterial or venous thrombotic event(s) at 30‑days after COVID‑19 diagnosis.
Results: 2275 patients were included. After PSM, 1270 patients remained in the study (635 on VKAs; 635 on DOACs). 
VKA‑treated patients had similar risks and 30‑day event‑free survival than patients on DOACs regarding all‑cause 
mortality, ICU admission/MV necessity, and ICH/gastrointestinal bleeding. The risk of any arterial or venous throm‑
botic event was 43% higher in the VKA cohort (hazard ratio 1.43, 95% confidence interval 1.03–1.98; Log‑Rank test 
p = 0.029).
Conclusion: In COVID‑19 outpatients with cardiometabolic diseases, prior use of DOAC therapy compared to VKA 
therapy at the time of COVID‑19 diagnosis demonstrated lower risk of arterial or venous thrombotic outcomes, with‑
out increasing the risk of bleeding.
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Introduction
Oral anticoagulants (OACs), including vitamin K antag-
onists (VKAs) and direct-acting OACs (DOACs), have 
been used for thromboprophylaxis in different clinical 
scenarios. In the pivotal clinical trials of stroke preven-
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to warfarin for preventing stroke/systemic embolism 
(SE), with lower rates of intracranial haemorrhage (ICH) 
in comparison with warfarin [1–4]. Similarly, in venous 
thromboembolism (VTE), dabigatran, rivaroxaban, 
apixaban and edoxaban were non-inferior to conven-
tional therapy in terms of efficacy and caused less bleed-
ing in a broad spectrum of patients [5–9]. These trials 
evidences are supported by data from real world and 
observational studies, where DOACs have demonstrated 
significantly lower rates for major bleeding and a positive 
net clinical benefit compared to VKAs [10–13]. In VTE 
patients, the use of DOACs has also been associated with 
a lower risk of VTE recurrence even after anticoagulant 
discontinuation [14, 15].
Coronavirus Disease 2019 (COVID-19) has shown 
to trigger endothelial dysfunction, inflammatory and 
hypercoagulable states [16–18]. The risk of thrombo-
sis is increased, and thromboembolic complications are 
relatively frequent in these patients, particularly in those 
patients with intensive care unit (ICU) admission [19–
22]. Thus, anticoagulation is now well-established for the 
management of COVID-19 patients [23–25]. However, a 
common limitation is that most of the evidence to date 
refers to the hospitalization context. Thus, it remains 
uncertain if prior OAC therapy in outpatients, especially 
amongst patients with multimorbidity, would poten-
tially influence the severity and clinical outcomes after 
COVID-19 diagnosis.
The aim of this study was to compare clinical outcomes 
30-days after COVID-19 diagnosis between outpatients 
with cardiometabolic disease on chronic VKA or DOAC 
therapy at time of COVID-19 diagnosis, using a propen-
sity score matching (PSM) approach.
Methods
Data from TriNetX, a global federated health research 
network with real-time updates of anonymised electronic 
medical records (EMRs) mainly from the United States 
(US), were used. The network includes healthcare organi-
sations (HCOs, academic medical centres, specialty 
physician practices and community hospitals), with accu-
mulated data for more than 71 million patients. Approxi-
mately, 18 million adult patients had a visit in a TriNetX 
HCO during 2020.
The inclusion criteria were ≥ 18  years and outpatient 
with COVID-19 and cardiometabolic disease recorded 
in EMRs between 20 January 2020 and 15 February 2021. 
COVID-19 was identified using criteria provided by Tri-
NetX based on Centers for Disease Control and Preven-
tion (CDC) coding guidelines [26]. COVID-19 status was 
determined using codes in EMRs or a positive test result 
identified with COVID-19-specific laboratory codes. 
Specifically, COVID-19 was identified by one or more of 
the International Classification of Diseases, Tenth Revi-
sion, Clinical Modification (ICD-10-CM) codes in the 
EMRs of the patients (Additional file  1: Table  S1). The 
inclusion date start was set as 20 January 2020 because 
COVID-19 was first confirmed in the US on this date, 
and the TriNetX network is predominately US-based 
[27]. Cardiometabolic disease was defined as the combi-
nation of diabetes mellitus (ICD-10-CM code: E08-E13) 
and any disease of the circulatory system (ICD-10-CM 
code: I00-I99). In addition, all patients should have 
OAC therapy in the one-year period prior to COVID-19 
recorded in their EMRs, and remained on this therapy 
at COVID-19 diagnosis. During 1-year period prior to 
COVID-19 diagnosis, patients must not be hospitalized 
to ensure they are stable outpatients.
All patients were then stratified by OAC prescription. 
The DOAC group included outpatients who received 
either dabigatran, apixaban, rivaroxaban or edoxaban for 
at least 1 year before COVID-19 diagnosis, whereas the 
VKA group included outpatients who received warfarin 
under the same conditions. Patients were excluded if they 
received concomitant anticoagulant therapy (oral or par-
enteral). Baseline demographics, comorbidities and med-
ication use were also captured from the patient EMRs.
The searches were run in TriNetX on 30 April 2021, 
which allowed for at least 30-days of follow-up for all 
participants from the time all conditions were fulfilled. 
When the searchers were run, there were 61 participating 
HCOs within the TriNetX research network.
Follow‑up and clinical outcomes
All patients were followed-up for up to 30-days after 
COVID-19 diagnosis. Primary outcomes included all-
cause mortality, ICU admission/mechanical ventilation 
(MV) necessity, ICH/gastrointestinal bleeding, and the 
composite of any arterial or venous thrombotic event 
(any of the following: myocardial infarction, other arterial 
thrombosis, VTE, or ischemic stroke/transient ischemic 
attack [TIA]/SE). The secondary outcomes were hospital 
admission, myocardial infarction, VTE, ischemic stroke/
TIA/SE, and all bleeding. Further details about the ICD-
10-CM codes used for the identification of every out-
come are included in Additional file 1: Table S2.
Ethical issues
As a federated network, research studies using TriNetX 
do not require ethical approval. To comply with legal 
frameworks and ethical guidelines guarding against data 
re-identification, the identity of participating HCOs 
and their individual contribution to each dataset are 
not disclosed. The TriNetX platform only uses aggre-
gated counts and statistical summaries of de-identified 
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information. No protected health information or per-
sonal data are made available to the users of the platform.
Statistical analysis
Continuous variables were expressed as mean and 
standard deviation (SD), and tested for differences with 
independent-sample t tests. Categorical variables were 
expressed as absolute frequencies and percentages, and 
tested for differences with chi-squared test.
The TriNetX platform was used to run 1:1 PSM using 
logistic regression. The platform uses ‘greedy near-
est-neighbour matching’ with a caliper of 0.1 pooled 
standard deviations and difference between propensity 
scores ≤ 0.1. We assessed covariate balance between 
groups using standardised mean differences (SMDs). 
Any baseline characteristic with a SMD between cohorts 
lower than 0.1 is considered well matched [28].
Cox proportional Hazard Ratios (HRs) with 95% con-
fidence intervals (CI) for 30-days outcomes were cal-
culated following PSM. Kaplan–Meier survival curves 
were also produced with Log-Rank tests after PSM. No 
imputations were made for missing data. Two-sided 
p-values < 0.05 were accepted as statistically significant. 
Statistical analysis was performed using the TriNetX 
Analytics function in the online research platform.
Results
Overall, 2275 patients (mean age 67.7 ± 12.8 years, 1222 
[53.7%] males) with COVID-19 and cardiometabolic dis-
ease were included. Of these, 648 (363 [56.0%] males, 
mean age of 67.9 ± 12.9  years) were on VKA therapy at 
the time of COVID-19 diagnosis, and 1627 (859 [52.8%] 
males, mean age 67.6 ± 12.8 years) were on DOACs.
There were no differences between cohorts regarding 
the main reasons for OAC (i.e. AF or previous pulmonary 
embolism). Other VTEs were more common in patients 
taking VKA therapy. In addition, patients on VKA were 
in general more comorbid, as demonstrated by the higher 
prevalence of hypertension, heart failure, ischemic heart 
disease, hyperlipidaemia, overweight/obesity, diseases of 
the nervous and digestive systems, acute kidney failure/
chronic kidney disease, and neoplasms (Table  1). After 
PSM, 1270 remained in the study, 635 individuals on 
VKA therapy and 635 on DOACs (i.e. proportion of 1:1), 
well balanced on age, gender, ethnicity, and comorbidities 
(Table 1).
Comparisons of clinical outcomes
In the initial populations, all event rates were numerically 
higher in the COVID-19 patients with cardiometabolic 
disease on prior VKA, which were significant for any 
arterial or venous thrombotic event (14.04% vs. 8.54%, 
p < 0.001), VTE (9.88% vs. 6.82%, p = 0.007), and ischemic 
stroke/TIA/SE (4.17% vs. 1.72%, p < 0.001). After PSM, 
the rate of any arterial or venous thrombotic event 
(14.02% vs. 9.61%, p = 0.015) and ischemic stroke/TIA/
SE (4.25% vs. 1.73%, p = 0.008) remained higher in users 
of VKA compared to users of DOACs. Further details are 
shown in Table 2.
In terms of the primary outcomes after PSM, there 
were no significant differences in the risks of all-cause 
mortality, ICU admission/MV necessity, or ICH/gastro-
intestinal bleeding between patients on VKA or DOACs. 
Thus, the risk for all-cause mortality was similar compar-
ing the VKA cohort and DOAC cohort (HR 0.70, 95% 
0.28–1.74). The risk of ICU admission/MV necessity 
in the VKA cohort was not significantly different com-
pared to the DOAC cohort (HR 1.31, 95% CI 0.55–3.10), 
and the risk of ICH/gastrointestinal bleeding was similar 
(HR 1.29, 95% CI 0.29–5.75). Event-free survival for these 
three outcomes was not different between cohorts, as 
assessed by the Kaplan–Meier analyses (Log-Rank tests: 
p = 0.442 for mortality; p = 0.543 for ICU admission/MV 
necessity; and p = 0.741 for ICH/gastrointestinal bleed-
ing) (Fig. 1).
The composite outcome of any arterial or venous 
thrombotic event was inferior in the DOAC cohort in 
comparison to the VKA cohort, as demonstrated by the 
43% higher risk in VKA users (HR 1.43, 95% CI 1.03–
1.98) and the lower event-free survival (Log-Rank test 
p = 0.029) (Fig. 1).
Secondary outcomes
Hospital admission was similar in VKA and DOAC 
patients (HR 0.98, 95% CI 0.50–1.92). Likewise, there 
were no significant differences in the risk of myocardial 
infarction between both groups (HR 1.46, 95% CI 0.41–
5.18), nor in the risk of VTE (HR 1.20, 95% CI 0.83–1.74). 
The risk of all bleeding events was not significantly differ-
ent in patients previously taking VKA (HR 2.24, 95% CI 
0.92–5.44) (Fig. 2).
The risk of suffering an ischemic stroke/TIA/SE at 
30-days after COVID-19 diagnosis was 2.42-fold higher 
in users of VKA compared to DOAC users (HR 2.42, 95% 
CI 1.20–4.88; Log-Rank test p = 0.011) (Fig. 2).
Sensitivity analysis
A sensitivity analysis was performed including only those 
patients fulfilling the initial inclusion/exclusion crite-
ria and AF, as this is the most common indication for 
OAC use. After PSM on a 1:1 proportion, 866 patients 
(mean age 71.2 ± 11.6  years, 508 [61%] males) with 
COVID-19, AF and other cardiometabolic disease were 
included, of which 433 (254 [58.7%] males, mean age of 
71.1 ± 12.2  years) were on VKA therapy at the time of 
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COVID-19 diagnosis, and 433 (254 [58.7%] males, mean 
age 71.3 ± 11.0 years) were on DOACs.
Overall, the risk for the primary outcomes in this sen-
sitivity analysis between patients on VKA or DOACs 
was similar compared to the main analysis. Thus, there 
were no significant differences in VKA or DOAC-treated 
patients regarding all-cause mortality (HR 1.36, 95% CI 
0.47–3.91; Log-Rank test p = 0.570), ICU admission/
MV necessity (HR 1.35, 95% CI 0.57–3.19; Log-Rank test 
p = 0.499), and ICH/ gastrointestinal bleeding (HR 0.34, 
95% CI 0.07–1.67; Log-Rank test p = 0.162). The risk of 
composite outcome of any arterial or venous throm-
botic event was higher in the VKA cohort compared to 
the DOAC cohort (HR 1.80, 95% CI 1.04–3.12), with a 
significantly lower event-free survival (Log-Rank test 
p = 0.033).
Concerning the secondary outcomes, the risks of hos-
pital admission (HR 0.94, 95% CI 0.46–1.90; Log-Rank 
test p = 0.859), myocardial infarction (OR 0.58, 95% CI 
0.17–1.97; Log-Rank test p = 0.372), VTE (HR 1.48, 95% 
CI 0.69–3.19; Log-Rank test p = 0.315), and all bleed-
ing events (HR 1.14, 95% CI 0.44–2.96; Log-Rank test 
p = 0.782), was also similar in patients previously taking 
VKA or DOACs. The risk of ischemic stroke/TIA/SE was 
increased in VKA users (HR 3.69, 95% CI 1.37–9.93), 
and Kaplan–Meier analysis demonstrated a significantly 
lower event-free survival in the VKA-treated cohort 
(Log-Rank test p = 0.006).
Discussion
In this study including COVID-19 outpatients with cardi-
ometabolic disease, patients taking VKA before COVID-
19 diagnosis showed a 43% higher 30-day risk of any 
arterial/venous thrombotic event and ischemic stroke/
TIA/SE, compared to patients taking DOAC, adjusting 
for comorbidities using PSM. These results were consist-
ent also in COVID-19 patients with AF and other cardio-
metabolic disease.
Previous studies have shown that cardiometabolic mul-
timorbidity is common among patients with COVID-19, 
and it is associated with a higher risk of hospitalization 
and a worsened prognosis [29–32]. In particular, diabe-
tes is frequent in these patients [33, 34], and associated 
with an increased risk of complications, likely due to 
clustering with other conditions [29]. Simultaneously, 
several cardiovascular diseases, including hypertension, 
cerebrovascular disease and coronary artery disease, are 
prevalent in COVID-19 patients, and are associated with 
a higher risk of adverse outcomes [35]. Given that the 
presence of cardiometabolic disease is not uncommon in 
patients with Severe Acute Respiratory Syndrome Coro-
navirus 2 (SARS-CoV-2) infection, this might have major 
implications for prognosis in this condition.
It is well established that COVID-19 increases the 
risk of arterial and venous thrombosis [20, 21], lead-
ing to the research focus on thromboinflammation and 
antithrombotic therapy, particularly in anticoagulation 
therapy [23, 25, 36, 37]. Many patients had preexist-
ing cardiovascular diseases and were already on OAC 
therapy when they were diagnosed of COVID-19 [38]. 
Hence, the role of prior OAC therapy in the context of 
COVID-19 is gaining interest. For example, a recent 
study concluded that prior use of therapeutic antico-
agulation was not associated with improved survival 
in hospitalized COVID-19 patients [39]. Similarly, a 
small study found that regular VKA use in hospitalized 
Table 2 Primary and secondary outcomes in patients on VKAs or DOAC at COVID‑19 diagnosis, before (unmatched) and after 
propensity score matching
DOAC: direct‑acting oral anticoagulant; ICH: intracranial haemorrhage; ICU: intensive care unit; MV: mechanical ventilation; SE: systemic embolism; TIA: transient 
ischemic attack; VKA: vitamin K antagonist
Outcomes Initial populations Propensity score matched populations
COVID‑19 














All‑cause mortality 10 (1.54%) 22 (1.35%) 0.913 10 (1.57%) 11 (1.73%) 0.826
ICU admission/MV necessity 12 (1.85%) 21 (1.29%) 0.378 12 (1.89%) 10 (1.57%) 0.667
ICH/gastrointestinal bleeding 10 (1.54%) 12 (0.74%) 0.145 10 (1.57%) 10 (1.57%) 1.000
Any arterial or venous thrombotic event 91 (14.04%) 139 (8.54%) < 0.001 89 (14.02%) 61 (9.61%) 0.015
Hospital admission 17 (2.62%) 42 (2.58%) 0.891 17 (2.68%) 17 (2.68%) 1.000
Myocardial infarction 10 (1.54%) 13 (0.80%) 0.190 10 (1.57%) 10 (1.57%) 1.000
Venous thromboembolism 64 (9.88%) 111 (6.82%) 0.007 62 (9.76%) 50 (7.87%) 0.235
All bleeding events 16 (2.45%) 18 (1.11%) 0.084 16 (2.52%) 10 (1.57%) 0.235
Ischemic stroke/TIA/SE 27 (4.17%) 28 (1.72%)  < 0.001 27 (4.25%) 11 (1.73%) 0.008
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frail older patients with COVID-19 was associated 
with increased mortality during the first week [40]. 
On the contrary, a retrospective study concluded that 
COVID-19 patients on OAC at the time of infection 
and throughout their disease course had significantly 
lower risk of all-cause mortality at 21 days [41]. Indeed, 
OAC therapy was associated with lower risk of all-
cause mortality in elderly AF patients with COVID-19 
[42], and more recently, the ACTION trial showed that 
among patients admitted with COVID-19 and elevated 
D-dimer, therapeutic anticoagulation was not superior 
to prophylactic anticoagulation; and rivaroxaban for 
stable patients and enoxaparin for unstable patients 
increased major bleeding without improving clinical 
outcomes [43, 44].
Nevertheless, a common limitation of most studies 
(both, those with positive and negative results in favour 
of OACs) is the hospitalization setting. Such patients 
have already suffered deterioration of their baseline 
status, which has led to hospitalization and may be a 
manifestation of a more severe state of the SARS-CoV-2 
infection, with an increased risk of thrombosis, mortality, 
ICU admission, and MV. In these more severe patients, 
several confounding factors may be acting when evalu-
ating the potential role of previous OAC, and the differ-
ences between VKA and DOAC may be non-existent.
Fig. 1 Comparison of survival curves for the primary outcomes between patients on VKAs or DOACs at COVID‑19 diagnosis after propensity score 
matching. Purple line: Prior VKA use; Green line: Prior DOAC use
Fig. 2 Comparison of survival curves for the secondary outcomes between patients on VKAs or DOACs at COVID‑19 diagnosis after propensity 
score matching. Purple line: Prior VKA use; Green line: Prior DOAC use
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As a result, COVID-19 outpatients with cardiometa-
bolic diseases under anticoagulation therapy are a pop-
ulation with scarce data, and their management could 
be particularly complex. A recent study concluded 
that OAC therapy in high-risk AF patients was associ-
ated with a lower risk of receiving a positive COVID-19 
test and severe COVID-19 outcomes [45]. In turn, pre-
admission and in-hospital OAC therapy (either VKA or 
DOAC) were positively associated with higher survival 
in a study including elderly AF patients with COVID-19 
[46]. Although these prior studies did not observe dif-
ferences between VKA and DOACs, we found that VKA 
users had a higher risk of thromboembolism, which 
supported several previous studies demonstrating that 
DOAC therapy is more effective and even as safe as VKA 
therapy [47, 48].
DOACs have recently demonstrated to be superior in 
comparison to VKAs among patients with different con-
ditions. For example, DOACs was associated with lower 
long-term all-cause mortality than VKAs in AF patients 
who were successfully discharged after transcatheter aor-
tic valve replacement [49]. In addition, in patients with 
left ventricular thrombi, there is a significant reduction 
in stroke with the use of DOACs, without an increase in 
bleeding [50], and among diabetic AF patients, DOACs 
are associated with a lower risk of thromboembolism, 
major bleeding, and major adverse limb events than 
VKAs [51].
Nonetheless, the published data for DOACs in the field 
of COVID-19 is conflicting. In the context of hospitaliza-
tion, many of the COVID-19 patients with prior DOAC 
therapy will be switched to heparins because they are 
expected to receive medications interacting with DOACs, 
or have coagulation system and homeostasis disorders 
[52, 53]. For this reason, it is necessary to act before 
hospitalization in these especially vulnerable patients. 
Since our results show that within 30 days of COVID-19 
diagnosis there is an increased risk of complications in 
patients on prior VKA, whenever possible, a change to a 
DOAC should be considered. This may not only reduce 
the risk of adverse events in the case of COVID-19, but 
also the need for monitoring and therefore the number 
of visits to health care centers and the social contact that 
this implies, which can contribute to a lower risk of infec-
tion [54]. Some societies consider that DOAC could be 
maintained even during hospitalization, based on clini-
cal conditions and assessment for drug–drug interactions 
[21, 55, 56].
However, there are some indications such as antiphos-
pholipid syndrome or prosthetic heart valves for which 
DOACs are not approved. In such patients, a switch from 
VKA to DOACs is not possible, and therefore other inter-
ventions are required to achieve and maintain the highest 
quality of anticoagulation in order to reduce the risk of 
worse clinical outcomes when on VKAs. These include 
the identification and modification of causes of poor 
anticoagulation control with VKAs (eg. potential phar-
macologic interactions), routine assessment of adherence 
to treatment, patient-centred education/counselling and 
educational programs for healthcare professionals, the 
use of multidose drug dispensing systems, self-manage-
ment of VKA therapy, specialized anticoagulation clinics 
to improve adherence and a more careful follow-up [57, 
58]. Due to the COVID-19 pandemic, telemedicine visits 
and telehealth programs may help to achieve these objec-
tives while minimize exposure risks for both patients and 
healthcare professionals [59].
Limitations
There are some limitations that need to be acknowledged. 
First, the data were collected from the HCO EMRs and 
some health conditions may be underreported. Record-
ing of ICD codes in EMR may vary by factors including 
age, comorbidities, severity of illness, length of in-hospi-
tal stay, and in-hospital mortality. Further residual con-
founding may include lifestyle factors such as alcohol 
consumption and physical activity, which were not 
available.
Propensity scores are a method used to balance covari-
ates, but in observational studies propensity scores are 
estimated and therefore there is no certainty that the 
propensity score was 100% accurate. We also could not 
determine if there was any impact of attending different 
HCOs because of data privacy restrictions. We exam-
ined all deaths of the included patients captured within 
the TriNetX network; however, deaths outside of the par-
ticipating HCOs are not well captured. It should also be 
noted that we had not access to time in therapeutic range 
of International Normalized Ratio (INR) for VKA-treated 
patients, so there are uncertainties about the quality of 
anticoagulation therapy in these patients. Finally, our 
main objective was to investigate the association of prior 
VKA or DOAC therapy with short-term prognosis after 
outpatient COVID-19 diagnosis. For this reason we did 
not take into account the anticoagulation therapy once 
patients were diagnosed of COVID-19, since our inter-
est was on the previous use of VKAs or DOACs. For the 
same reason, we have not analyzed the potential role 
of other pharmacological therapies such as antidiabet-
ics agents or insulin, although we recognize influence of 
such therapies on outcomes.
Conclusion
In COVID-19 outpatients with cardiometabolic dis-
eases, prior use of DOAC therapy compared to VKA 
therapy at the time of COVID-19 diagnosis might 
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reduce the risk of composite arterial or venous throm-
botic outcomes, without increasing the risk of bleeding.
Abbreviations
AF: Atrial fibrillation; CDC: Centres for Disease Control and Prevention; CI: 
Confidence interval; COVID‑19: Coronavirus Disease 2019; DOAC: Direct‑acting 
oral anticoagulant; EMR: Electronic medical record; HCO: Healthcare organisa‑
tion; HR: Hazard ratio; ICH: Intracranial haemorrhage; ICU: Intensive care unit; 
INR: International normalized ratio; MV: Mechanical ventilation; OAC: Oral 
anticoagulant; PSM: Propensity score matching; SARS‑CoV‑2: Severe Acute 
Respiratory Syndrome Coronavirus 2; SD: Standard deviation; SE: Systemic 
embolism; SMD: Standardised mean difference; TIA: Transient ischemic attack; 
VKA: Vitamin K antagonist; VTE: Venous thromboembolism.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12933‑ 021‑ 01368‑6.
Additional file 1: Table S1. ICD‑10‑CM codes and LOINCs for the identifi‑




JMR‑C and GYHL designed the study. EF‑E and PU provided TriNetX access and 
made a critical revision. JMR‑C and GYHL acquired data, performed statisti‑
cal analyses and drafted the manuscript. SLH, BJRB and FM made a critical 
revision. All authors approved the final content for journal submission and 
publication. All authors read and approved the final manuscript.
Funding
The authors received no specific funding for this work.
Availability of data and materials
The data, analytic methods, and study materials will not be made available to 
other researchers for purposes of reproducing the results or replicating the 
procedure because some materials are used for other unpublished projects.
Declarations
Ethics approval and consent to participate
As a federated network, research studies using TriNetX do not require ethical 
approval. To comply with legal frameworks and ethical guidelines guarding 
against data re‑identification, the identity of participating HCOs and their 
individual contribution to each dataset are not disclosed. The TriNetX platform 
only uses aggregated counts and statistical summaries of de‑identified infor‑
mation. No protected health information or personal data are made available 




JMR‑C has received a grant from Sociedad Española de Trombosis y Hemo‑
stasia (grant for short international training stays 2020), and the First Contact 
Initiative Grant 2020 from the European Society of Cardiology Council on Basic 
Cardiovascular Science. SLH has received a grant from Bristol Myers Squibb 
(BMS). FM: consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and 
AstraZeneca; research grants from Bayer. GYHL: Consultant and speaker for 
BMS/Pfizer, Boehringer Ingelheim and Daiichi‑Sankyo. No fees are received 
personally. Other authors report no conflict of interest.
Author details
1 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liv‑
erpool Heart & Chest Hospital, Liverpool, UK. 2 Department of Cardiology, 
Hospital Clínico Universitario Virgen de La Arrixaca, University of Murcia, Insti‑
tuto Murciano de Investigación Biosanitaria (IMIB‑Arrixaca), CIBERCV, Murcia, 
Spain. 3 Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. 
4 Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical 
Sciences, University of Liverpool, Liverpool, UK. 5 TriNetX LLC., Cambridge, MA, 
USA. 6 TriNetX LLC., London, UK. 7 Department of Clinical Medicine, Aalborg 
University, Aalborg, Denmark. 
Received: 22 July 2021   Accepted: 23 August 2021
References
 1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, 
et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J 
Med. 2009;361(12):1139–51.
 2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, 
et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J 
Med. 2011;365(11):981–92.
 3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivar‑
oxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 
2011;365(10):883–91.
 4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, 
et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J 
Med. 2013;369(22):2093–104.
 5. Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, 
et al. Edoxaban versus warfarin for the treatment of symptomatic venous 
thromboembolism. N Engl J Med. 2013;369(15):1406–15.
 6. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral 
apixaban for the treatment of acute venous thromboembolism. N Engl J 
Med. 2013;369(9):799–808.
 7. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, 
et al. Extended use of dabigatran, warfarin, or placebo in venous throm‑
boembolism. N Engl J Med. 2013;368(8):709–18.
 8. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti 
P, et al. Treatment of acute venous thromboembolism with dabigatran or 
warfarin and pooled analysis. Circulation. 2014;129(7):764–72.
 9. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, 
et al. Oral rivaroxaban for symptomatic venous thromboembolism. N 
Engl J Med. 2010;363(26):2499–510.
 10. Sun Z, Liu Y, Zhang Y, Guo X, Xu Y. Differences in safety and efficacy of oral 
anticoagulants in patients with non‑valvular atrial fibrillation: a Bayesian 
analysis. Int J Clin Pract. 2018;74:e13308.
 11. Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, et al. 
Comparative stroke, bleeding, and mortality risks in older medicare 
patients treated with oral anticoagulants for nonvalvular atrial fibrillation. 
Am J Med. 2019;132(5):596–604.
 12. Inohara T, Xian Y, Liang L, Matsouaka RA, Saver JL, Smith EE, et al. Associa‑
tion of intracerebral hemorrhage among patients taking non‑vitamin K 
antagonist vs vitamin K antagonist oral anticoagulants with in‑hospital 
mortality. JAMA. 2018;319(5):463–73.
 13. De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, et al. The 
non‑vitamin K antagonist oral anticoagulants in heart disease: section 
V‑special situations. Thromb Haemost. 2019;119(1):14–38.
 14. Campello E, Spiezia L, Simion C, Tormene D, Camporese G, Dalla Valle F, 
et al. Direct oral anticoagulants in patients with inherited thrombophilia 
and venous thromboembolism: a prospective cohort study. J Am Heart 
Assoc. 2020;9(23):e018917.
 15. Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M. Direct oral 
anticoagulants in patients with venous thromboembolism and throm‑
bophilia: a systematic review and meta‑analysis. J Thromb Haemost. 
2019;17(4):645–56.
 16. Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and 
antithrombotic treatment in coronavirus 2019: a new challenge. Thromb 
Haemost. 2020;120(6):949–56.
Page 10 of 11Rivera‑Caravaca et al. Cardiovasc Diabetol          (2021) 20:176 
 17. Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, 
et al. Features of severe COVID‑19: a systematic review and meta‑analysis. 
Eur J Clin Invest. 2020;50(10):e13378.
 18. Sjöström A, Wersäll J, Warnqvist A, Farm M, Magnusson M, Oldner A, et al. 
Platelet count rose while d‑dimer levels dropped as deaths and thrombo‑
sis declined, an observational study on anticoagulation shift in COVID‑19. 
Thromb Haemost. 2021. https:// doi. org/ 10. 1055/a‑ 1477‑ 3829.
 19. Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Matin S, et al. 
Intermediate vs standard‑dose prophylactic anticoagulation in patients 
with COVID‑19 admitted to ICU: ninety‑day results from the INSPIRATION 
Trial. Thromb Haemost. 2021. https:// doi. org/ 10. 1055/a‑ 1485‑ 2372.
 20. Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB, 
et al. Registry of arterial and venous thromboembolic complications in 
patients with COVID‑19. J Am Coll Cardiol. 2020;76(18):2060–72.
 21. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. 
COVID‑19 and thrombotic or thromboembolic disease: implications for 
prevention, antithrombotic therapy, and follow‑up. J Am Coll Cardiol. 
2020;75(23):2950–73.
 22. Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, 
et al. Heparin in COVID‑19 patients is associated with reduced in‑hospital 
mortality: the Multicenter Italian CORIST Study. Thromb Haemost. 
2021;121(8):1054–65.
 23. Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, 
Kordzadeh‑Kermani E, Van Tassell BW, et al. Recent randomized trials of 
antithrombotic therapy for patients with COVID‑19: JACC State‑of‑the‑Art 
Review. J Am Coll Cardiol. 2021;77(15):1903–21.
 24. Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. Prevention and 
treatment of venous thromboembolism associated with coronavirus 
disease 2019 infection: a consensus statement before guidelines. Thromb 
Haemost. 2020;120(6):937–48.
 25. Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghos‑
sian C, et al. Pharmacological agents targeting thromboinflammation in 
COVID‑19: review and implications for future research. Thromb Haemost. 
2020;120(7):1004–24.
 26. Centers‑for‑Disease‑Control‑and‑Prevention. ICD‑10‑CM official coding 
guidelines ‑ supplement coding encounters related to COVID‑19 coro‑
navirus outbreak 2020 [02‑03‑2021. https:// www. cdc. gov/ nchs/ data/ icd/ 
ICD‑ 10‑ CM‑ Offic ial‑ Coding‑ Gudan ce‑ Inter im‑ Advice‑ coron avirus‑ feb‑ 20‑ 
2020. pdf.
 27. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. 
First case of 2019 novel coronavirus in the United States. N Engl J Med. 
2020;382(10):929–36.
 28. Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–8.
 29. Maddaloni E, D’Onofrio L, Alessandri F, Mignogna C, Leto G, Pascarella G, 
et al. Cardiometabolic multimorbidity is associated with a worse Covid‑19 
prognosis than individual cardiometabolic risk factors: a multicentre 
retrospective study (CoViDiab II). Cardiovasc Diabetol. 2020;19(1):164.
 30. Pellicori P, Doolub G, Wong CM, Lee KS, Mangion K, Ahmad M, et al. 
COVID‑19 and its cardiovascular effects: a systematic review of preva‑
lence studies. Cochrane Database Syst Rev. 2021;3:CD013879.
 31. Svensson P, Hofmann R, Häbel H, Jernberg T, Nordberg P. Association 
between cardiometabolic disease and severe COVID‑19: a nationwide 
case‑control study of patients requiring invasive mechanical ventilation. 
BMJ Open. 2021;11(2):e044486.
 32. O’Hearn M, Liu J, Cudhea F, Micha R, Mozaffarian D. Coronavirus disease 
2019 hospitalizations attributable to cardiometabolic conditions in the 
United States: a comparative risk assessment analysis. J Am Heart Assoc. 
2021;10(5):e019259.
 33. Scalsky RJ, Chen YJ, Desai K, O’Connell JR, Perry JA, Hong CC. Baseline 
cardiometabolic profiles and SARS‑CoV‑2 infection in the UK Biobank. 
PLoS ONE. 2021;16(4):e0248602.
 34. Harrison SL, Fazio‑Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comor‑
bidities associated with mortality in 31,461 adults with COVID‑19 in the 
United States: a federated electronic medical record analysis. PLoS Med. 
2020;17(9):e1003321.
 35. Harrison SL, Buckley BJR, Rivera‑Caravaca JM, Zhang J, Lip GYH. Cardio‑
vascular risk factors, cardiovascular disease and COVID‑19: An umbrella 
review of systematic reviews. Eur Heart J Qual Care Clin Outcomes. 
2021;7(4):330–9.
 36. McBane RD 2nd, Torres Roldan VD, Niven AS, Pruthi RK, Franco PM, 
Linderbaum JA, et al. Anticoagulation in COVID‑19: a systematic review, 
meta‑analysis, and rapid guidance from Mayo Clinic. Mayo Clin Proc. 
2020;95(11):2467–86.
 37. Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic thromboprophy‑
laxis and thrombosis in hospitalized patients with COVID‑19: a pooled 
analysis. Thromb Haemost. 2021;121(1):76–85.
 38. Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, 
Fazeli B, et al. Guidance for the management of patients with vascular 
disease or cardiovascular risk factors and COVID‑19: position paper from 
VAS‑European Independent Foundation in angiology/vascular medicine. 
Thromb Haemost. 2020;120(1):1597–628.
 39. Spiegelenberg JP, van Gelder M, Maas ML, Hovens MMC, Esselink A, 
Dofferhoff ASM, et al. Prior use of therapeutic anticoagulation does 
not protect against COVID‑19 related clinical outcomes in hospitalized 
patients: a propensity score‑matched cohort study. Br J Clin Pharmacol. 
2021. https:// doi. org/ 10. 1111/ bcp. 14877.
 40. Ménager P, Brière O, Gautier J, Riou J, Sacco G, Brangier A, et al. Regular 
use of VKA prior to COVID‑19 associated with lower 7‑day survival in hos‑
pitalized frail elderly COVID‑19 patients: the GERIA‑COVID cohort study. 
Nutrients. 2020;13(1):39.
 41. Harrison RF, Forte K, Buscher MG Jr, Chess A, Patel A, Moylan T, et al. The 
association of preinfection daily oral anticoagulation use and all‑cause in 
hospital mortality from novel coronavirus 2019 at 21 days: a retrospective 
cohort study. Crit Care Explor. 2021;3(1):e0324.
 42. Denas G, Gennaro N, Ferroni E, Fedeli U, Lorenzoni G, Gregori D, et al. 
Reduction in all‑cause mortality in COVID‑19 patients on chronic oral 
anticoagulation: a population‑based propensity score matched study. Int 
J Cardiol. 2021;329:266–9.
 43. Lopes RD, de Barros ESPGM, Furtado RHM, Macedo AVS, Ramacciotti E, 
Damini LP, et al. Randomized clinical trial to evaluate a routine full anti‑
coagulation strategy in patients with coronavirus infection (SARS‑CoV2) 
admitted to hospital: rationale and design of the ACTION (AntiCoagulaT‑
lon cOroNavirus)‑Coalition IV Trial. Am Heart J. 2021;238:1–11.
 44. Lopes RD, Alexander JH. Coalition ACTION Trial: Randomized Clinical Trial 
To Evaluate A Routine Full Anticoagulation Strategy In Patients With Coro‑
navirus Infection (SARS‑CoV‑2) Admitted To Hospital. American College of 
Cardiology (ACC) meeting ‑ ACC212021.
 45. Wong AY, Tomlinson L, Brown JP, Elson W, Walker AJ, Schultze A, et al. 
Association between oral anticoagulants and COVID‑19 related out‑
comes: two cohort studies. 2021:2021.04.30.21256119.
 46. Fumagalli S, Trevisan C, Del Signore S, Pelagalli G, Volpato S, Gareri P, et al. 
COVID‑19 and atrial fibrillation in older patients. Does oral anticoagulant 
therapy provide a survival benefit? An insight from the GeroCovid Regis‑
try. Thromb Haemost. 2021. https:// doi. org/ 10. 1055/a‑ 1503‑ 3875.
 47. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. 
Effectiveness and safety of oral anticoagulants among nonvalvular atrial 
fibrillation patients. Stroke. 2018;49(12):2933–44.
 48. Pastori D, Menichelli D, Del Sole F, Pignatelli P, Violi F. Long‑term risk of 
major adverse cardiac events in atrial fibrillation patients on direct oral 
anticoagulants. Mayo Clin Proc. 2021;96(3):658–65.
 49. Kawashima H, Watanabe Y, Hioki H, Kozuma K, Kataoka A, Nakashima 
M, et al. Direct oral anticoagulants versus vitamin K antagonists in 
patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv. 
2020;13(22):2587–97.
 50. Michael F, Natt N, Shurrab M. Direct oral anticoagulants vs vitamin K 
antagonists in left ventricular thrombi: a systematic review and meta‑
analysis. CJC Open. 2021.
 51. Chan YH, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, et al. Effectiveness, safety, 
and major adverse limb events in atrial fibrillation patients with con‑
comitant diabetes mellitus treated with non‑vitamin K antagonist oral 
anticoagulants. Cardiovasc Diabetol. 2020;19(1):63.
 52. Aly R, Gupta S, Singh B, Kaur P, Kim K, Gupta S. The use of direct acting 
oral anticoagulants in patients with COVID‑19 infection. J Commun Hosp 
Intern Med Perspect. 2021;11(2):184–6.
 53. Testa S, Prandoni P, Paoletti O, Morandini R, Tala M, Dellanoce C, et al. 
Direct oral anticoagulant plasma levels’ striking increase in severe 
COVID‑19 respiratory syndrome patients treated with antiviral agents: the 
Cremona experience. J Thromb Haemost. 2020;18(6):1320–3.
 54. Vivas D, Roldán V, Esteve‑Pastor MA, Roldán I, Tello‑Montoliu A, Ruiz‑
Nodar JM, et al. Recommendations on antithrombotic treatment during 
the COVID‑19 pandemic. Position statement of the Working Group on 
Page 11 of 11Rivera‑Caravaca et al. Cardiovasc Diabetol          (2021) 20:176  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
Cardiovascular Thrombosis of the Spanish Society of Cardiology. Rev Esp 
Cardiol. 2020;73(9):749–57.
 55. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH 
interim guidance on recognition and management of coagulopathy in 
COVID‑19. J Thromb Haemost. 2020;18(5):1023–6.
 56. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. Euro‑
pean heart rhythm association practical guide on the use of non‑vitamin 
K antagonist oral anticoagulants in patients with atrial fibrillation. EP 
Europace. 2021. https:// doi. org/ 10. 1093/ europ ace/ euab0 65.
 57. Clarkesmith DE, Pattison HM, Lip GYH, Lane DA. Educational intervention 
improves anticoagulation control in atrial fibrillation patients: the TREAT 
randomised trial. PloS ONE. 2013;8(9):e74037.
 58. Prochaska JH, Hausner C, Nagler M, Göbel S, Eggebrecht L, Panova‑
Noeva M, et al. Subtherapeutic anticoagulation control under treatment 
with vitamin K‑antagonists‑data from a specialized coagulation service. 
Thromb Haemost. 2019;119(8):1347–57.
 59. Linz D, Pluymaekers N, Hendriks JM. TeleCheck‑AF for COVID‑19. Eur Heart 
J. 2020;41(21):1954–5.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
